openPR Logo
Press release

At-Home DOA Testing Market Overview, Growth Drivers and Forecast Report 2023 by Top Key Players Analysis - UCP Biosciences, Inc., Orient New Life Medical Co. Ltd., Express Diagnostics Int’l Inc., Psychemedics Corporation, Phamatech Inc.

10-26-2018 09:08 AM CET | Health & Medicine

Press release from: Prescient & Strategic Intelligence

At-Home DOA Testing Market Overview, Growth Drivers

Global at-home DOA testing market is projected to attain a size of $831.9 million by 2023. The market is mainly driven by the increased production and trade of illicit drugs worldwide, growing use of illicit drugs amongst teenagers, and initiatives by government organizations to reduce the level of drug abuse.

Explore report sample at: https://www.psmarketresearch.com/market-analysis/at-home-doa-testing-market/report-sample

On the basis of various types of products, the at-home DOA testing market has been categorized into rapid DOA test kits and breath analyzers. The market for rapid DOA test kits is expected to witness faster growth during the forecast period, attributed to the increasing adoption of various types of rapid DOA test kits, including test cups and dip cards. Also, these test kits are much cheaper as compared to breath analyzers.

Further, the rapid DOA test kits are bifurcated into test cups, test strips, test dip cards, and other types of kits. Amongst all these, the DOA test cups dominated the global rapid DOA test kits market in 2017. Extensive use of test cups for at-home urine drug testing is a key factor driving the market for this product category.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=at-home-doa-testing-market

The companies operating in the at-home DOA testing industry are acquiring other firms and establishing their presence in different economies to increase their market share. Abbott Laboratories (Abbott) being a major player in the production of at-home DOA testing products acquired Alere Inc. in 2017, to increase its share in the point-of-care testing diagnostics market. The addition of this business aligns with Abbott's strategy for the growth of company and complements the leadership positions across its other businesses, which include medical devices, nutritional supplements, and pharmaceuticals.

Browse report at: http://bit.ly/2Oct9W0

Some of the other key players in the at-home DOA testing industry are UCP Biosciences Inc., Orient New Life Medical Co. Ltd., Express Diagnostics Int’l Inc., Assure Tech (Hangzhou) Co. Ltd., Psychemedics Corporation, Confirm BioSciences, Phamatech Inc., Home Health (U.K.) Ltd., and Quest Products Inc.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release At-Home DOA Testing Market Overview, Growth Drivers and Forecast Report 2023 by Top Key Players Analysis - UCP Biosciences, Inc., Orient New Life Medical Co. Ltd., Express Diagnostics Int’l Inc., Psychemedics Corporation, Phamatech Inc. here

News-ID: 1330692 • Views:

More Releases from Prescient & Strategic Intelligence

Biobanking Services Market by Biobank Type, Service Type, Ownership, Application and Geography Forecast to 2024 - P&S Intelligence
Biobanking Services Market by Biobank Type, Service Type, Ownership, Application …
The global biobanking services market is expected to broaden during the forecast period, mainly on account of growing prevalence of chronic diseases, use of blood biomarkers in early detection of various types of cancersincreasing genomic research activities for studying diseases, growing trend of conserving cord blood stem cells of newborns, surging government and private funding to support regenerative medicine research, and growing need for cost-effective drug discovery and development. Download free
Patient Engagement Solutions Market 2013-2023 by Key Companies are - athenahealth, Cerner Corporation, IBM, eClinicalWorks, InterSystems, Epic
Patient Engagement Solutions Market 2013-2023 by Key Companies are - athenahealt …
The patient engagement solutions market for software is expected to reach $12.3 billion by 2023, registering a CAGR of 16.6% during the forecast period. Patient engagement software is increasingly being adopted by healthcare facilities, as it helps simplify complex patient health data and can also be customized according to requirements. Download free report sample at: https://www.psmarketresearch.com/market-analysis/patient-engagement-solutions-market/report-sample During the forecast period, the patient engagement solutions market is expected to witness the highest demand
Peptide Therapeutics Market 2024 with Top Key Players are Sanofi, Teva Pharmaceuticals, Novartis, Ipsen, Amgen, PolyPeptide Group
Peptide Therapeutics Market 2024 with Top Key Players are Sanofi, Teva Pharmaceu …
The global peptide therapeutics market is growing significantly due to the increasing prevalence of cardiovascular diseases and cancer, advances in peptide therapeutics manufacturing technology, and increasing healthcare expenditure. In addition, growing research and development activities along with a rich peptide therapeutics pipeline is expected to support the growth of the peptide therapeutics market. Patent expiration of several peptide drugs in the coming years will create ample opportunities for the global
ER+ Breast Cancer Pipeline to Witness Huge R&D Investment in the Coming Years | Chipscreen Biosciences, Eli Lilly and Company, Genentech
ER+ Breast Cancer Pipeline to Witness Huge R&D Investment in the Coming Years | …
The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates in different stages of development. Download free report sample at: https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis/report-sample *Chemical Genomics-Based Discovery Platform for ER+ breast cancer drug development Chipscreen Biosciences, Ltd. is using chemo genomics approach for the development of their drug candidates in ER+ breast cancer. The approach connects small molecule structures to disease targets and therapeutic functions to accelerate the discovery process

All 5 Releases


More Releases for DOA

Europe Drug of Abuse (DOA) Testing Market Outlook and Opportunities in Grooming …
For many people in Europe, especially emotionally disturbed teens, drugs are their best friends! But, as everyone knows, whether an addict or not, drugs are not good. Though they help people escape their troubles for a while, they lead to long-lasting ill-effects, such as risk of AIDS and hepatitis C. Due to the increasing concerns among relatives and friends about drug abuse by their loved ones, they are rapidly using
At-Home DOA Testing Market : Business Overview and Global Development Trends
Global At-Home DOA Testing Market: Overview Developing unlawful medications use among young people, rising number of initiatives by the administration organizations to lessen the medication misuse levels, and expanded creation of engineered cannabinoids, bath salts, and other rising medications are boosting the interest for at-home DOA testing items in the market. A report by Transparency Market Research (TMR) on the global at-home DOA testing market market is an adroit explanation
DOA Testing Market Size, Leaders, Segment Analysis and Forecast Report 2023
The increasing adoption of drug of abuse (DOA) testing at the organizational level, growing number of road accidents and deaths, and rising consumption of illicit drugs are some of the reasons behind the growth of the DOA testing market. In 2016, the market generated a revenue of $4.8 billion, and it is predicted to advance at a CAGR of 9.6% during the forecast period (2017–2023). Drug testing refers to the
Dioctyl Adipate (DOA) Market: Competitive Dynamics & Global Outlook 2024
LP INFORMATION offers a latest published report on Dioctyl Adipate (DOA) Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Dioctyl Adipate (DOA) market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.
At-Home Drug of Abuse (DOA) Testing Market Analysis with Research Report 2019
Global At-Home Drug of Abuse (DOA) Testing Market Size, Status and Forecast 2019-2025 This report examines the existing as well as sequential performance of the worldwide market. The report also calculates the forthcoming status of At-Home Drug of Abuse (DOA) Testing market based on thorough analysis. By providing exploratory techniques such as, qualitative and quantitative analysis the report presents a comprehensive analysis of market progression. Graphical presentation of information through charts,
Cunesoft GmbH and Jordan’s Drugstore Owners Association (DOA) Announce Strateg …
Munich, Germany and Amman, Jordan — August 21, 2019 — Today, Cunesoft GmbH and DOA have announced their strategic partnership that will make eCTD submission software available to the members of DOA. “We are very excited to be able to work with DOA and bring Cunesoft’s cune-eCTD solution to DOA’s 19 corporate members,” said Rainer Schwarz, CEO at Cunesoft. DOA’s members will now be able to easily license cune-eCTD in order